Cannabinoid 2 receptor is a novel anti-inflammatory target in experimental proliferative vitreoretinopathy

Anna Maria Szczesniak; Richard F. Porter; James T. Toguri; Joanna Borowska-Fielding; Simon Gebremeskel; Anuja Siwakoti; Brent Johnston; Christian Lehmann; Melanie E.M. Kelly

doi:10.1016/j.neuropharm.2016.08.030

Cannabinoid 2 receptor is a novel anti-inflammatory target in experimental proliferative vitreoretinopathy

Anna Maria Szczesniak, Richard F. Porter, James T. Toguri, Joanna Borowska-Fielding, Simon Gebremeskel, Anuja Siwakoti, Brent Johnston, Christian Lehmann, Melanie E.M. Kelly

科研成果: 期刊稿件 › 文献综述 › 同行评审

29 引用（Scopus）

源语言	英语
页（从-至）	627-638
页数	12
期刊	Neuropharmacology
卷	113
DOI	https://doi.org/10.1016/j.neuropharm.2016.08.030
出版状态	已出版 - 2月 1 2017

!!!ASJC Scopus Subject Areas

药理学
细胞和分子神经科学

访问文件

10.1016/j.neuropharm.2016.08.030

其它文件与链接

引用此

@article{33dc7a53418e48e3adfad0b78ee5c8c3,

title = "Cannabinoid 2 receptor is a novel anti-inflammatory target in experimental proliferative vitreoretinopathy",

author = "Szczesniak, {Anna Maria} and Porter, {Richard F.} and Toguri, {James T.} and Joanna Borowska-Fielding and Simon Gebremeskel and Anuja Siwakoti and Brent Johnston and Christian Lehmann and Kelly, {Melanie E.M.}",

note = "Funding Information: Supported by an operating grant to MEMK from the Canadian Institutes of Health Research (MOP-97768). Richard Porter was funded by a scholarship from the Dalhousie University Department of Ophthalmology and Visual Science: Dr. R. Evatt and Rita Mathers Graduate Scholarship. Publisher Copyright: {\textcopyright} 2016",

year = "2017",

month = feb,

day = "1",

doi = "10.1016/j.neuropharm.2016.08.030",

language = "English",

volume = "113",

pages = "627--638",

journal = "Neuropharmacology",

issn = "0028-3908",

publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Cannabinoid 2 receptor is a novel anti-inflammatory target in experimental proliferative vitreoretinopathy

AU - Szczesniak, Anna Maria

AU - Porter, Richard F.

AU - Toguri, James T.

AU - Borowska-Fielding, Joanna

AU - Gebremeskel, Simon

AU - Siwakoti, Anuja

AU - Johnston, Brent

AU - Lehmann, Christian

AU - Kelly, Melanie E.M.

N1 - Funding Information: Supported by an operating grant to MEMK from the Canadian Institutes of Health Research (MOP-97768). Richard Porter was funded by a scholarship from the Dalhousie University Department of Ophthalmology and Visual Science: Dr. R. Evatt and Rita Mathers Graduate Scholarship. Publisher Copyright: © 2016

PY - 2017/2/1

Y1 - 2017/2/1

UR - http://www.scopus.com/inward/record.url?scp=85003945982&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85003945982&partnerID=8YFLogxK

U2 - 10.1016/j.neuropharm.2016.08.030

DO - 10.1016/j.neuropharm.2016.08.030

M3 - Review article

C2 - 27569993

AN - SCOPUS:85003945982

SN - 0028-3908

VL - 113

SP - 627

EP - 638

JO - Neuropharmacology

JF - Neuropharmacology

ER -

Cannabinoid 2 receptor is a novel anti-inflammatory target in experimental proliferative vitreoretinopathy

!!!ASJC Scopus Subject Areas

访问文件

其它文件与链接

指纹

引用此